Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.

Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.

Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.

Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.

Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.

Objective: Suicide poses a significant public health concern with increasing prevalence in the general population, emphasizing the need for effective gatekeeper suicide prevention education. This study assesses the longitudinal effectiveness of the “Suicide CARE” gatekeeper training program within a general community sample. Suicide CARE is representative gatekeeper program in Korea. A total of 5 million individuals completed the training program of Suicide CARE in Korea to date. Methods: Participants were recruited through the Korea Suicide Prevention Association website, randomly assigned to the experimental (n=49) or control group (n=53). Pre- and post-training surveys, along with a 3-month follow-up, measured perceived knowledge, gatekeeper efficacy, preparedness, and attitudes toward suicide. Longitudinal effects were analyzed using repeated measures analysis of variance. Results: The experimental group showed significant improvement in perceived knowledge, gatekeeper efficacy, perceived preparedness, and some aspects of attitude towards suicide compared to the control group, with effects declining over time but remaining statistically significant at the 3-month follow-up test. Conclusion This study is the first to evaluate the longitudinal effectiveness of Suicide CARE in a community population. Strategic integration of evidence-based gatekeeper training programs like Suicide CARE can contribute to community suicide prevention initiatives.

Objective: Suicide poses a significant public health concern with increasing prevalence in the general population, emphasizing the need for effective gatekeeper suicide prevention education. This study assesses the longitudinal effectiveness of the “Suicide CARE” gatekeeper training program within a general community sample. Suicide CARE is representative gatekeeper program in Korea. A total of 5 million individuals completed the training program of Suicide CARE in Korea to date. Methods: Participants were recruited through the Korea Suicide Prevention Association website, randomly assigned to the experimental (n=49) or control group (n=53). Pre- and post-training surveys, along with a 3-month follow-up, measured perceived knowledge, gatekeeper efficacy, preparedness, and attitudes toward suicide. Longitudinal effects were analyzed using repeated measures analysis of variance. Results: The experimental group showed significant improvement in perceived knowledge, gatekeeper efficacy, perceived preparedness, and some aspects of attitude towards suicide compared to the control group, with effects declining over time but remaining statistically significant at the 3-month follow-up test. Conclusion This study is the first to evaluate the longitudinal effectiveness of Suicide CARE in a community population. Strategic integration of evidence-based gatekeeper training programs like Suicide CARE can contribute to community suicide prevention initiatives.

Objective: Suicide poses a significant public health concern with increasing prevalence in the general population, emphasizing the need for effective gatekeeper suicide prevention education. This study assesses the longitudinal effectiveness of the “Suicide CARE” gatekeeper training program within a general community sample. Suicide CARE is representative gatekeeper program in Korea. A total of 5 million individuals completed the training program of Suicide CARE in Korea to date. Methods: Participants were recruited through the Korea Suicide Prevention Association website, randomly assigned to the experimental (n=49) or control group (n=53). Pre- and post-training surveys, along with a 3-month follow-up, measured perceived knowledge, gatekeeper efficacy, preparedness, and attitudes toward suicide. Longitudinal effects were analyzed using repeated measures analysis of variance. Results: The experimental group showed significant improvement in perceived knowledge, gatekeeper efficacy, perceived preparedness, and some aspects of attitude towards suicide compared to the control group, with effects declining over time but remaining statistically significant at the 3-month follow-up test. Conclusion This study is the first to evaluate the longitudinal effectiveness of Suicide CARE in a community population. Strategic integration of evidence-based gatekeeper training programs like Suicide CARE can contribute to community suicide prevention initiatives.

Objective: Suicide poses a significant public health concern with increasing prevalence in the general population, emphasizing the need for effective gatekeeper suicide prevention education. This study assesses the longitudinal effectiveness of the “Suicide CARE” gatekeeper training program within a general community sample. Suicide CARE is representative gatekeeper program in Korea. A total of 5 million individuals completed the training program of Suicide CARE in Korea to date. Methods: Participants were recruited through the Korea Suicide Prevention Association website, randomly assigned to the experimental (n=49) or control group (n=53). Pre- and post-training surveys, along with a 3-month follow-up, measured perceived knowledge, gatekeeper efficacy, preparedness, and attitudes toward suicide. Longitudinal effects were analyzed using repeated measures analysis of variance. Results: The experimental group showed significant improvement in perceived knowledge, gatekeeper efficacy, perceived preparedness, and some aspects of attitude towards suicide compared to the control group, with effects declining over time but remaining statistically significant at the 3-month follow-up test. Conclusion This study is the first to evaluate the longitudinal effectiveness of Suicide CARE in a community population. Strategic integration of evidence-based gatekeeper training programs like Suicide CARE can contribute to community suicide prevention initiatives.

Objective: Suicide poses a significant public health concern with increasing prevalence in the general population, emphasizing the need for effective gatekeeper suicide prevention education. This study assesses the longitudinal effectiveness of the “Suicide CARE” gatekeeper training program within a general community sample. Suicide CARE is representative gatekeeper program in Korea. A total of 5 million individuals completed the training program of Suicide CARE in Korea to date. Methods: Participants were recruited through the Korea Suicide Prevention Association website, randomly assigned to the experimental (n=49) or control group (n=53). Pre- and post-training surveys, along with a 3-month follow-up, measured perceived knowledge, gatekeeper efficacy, preparedness, and attitudes toward suicide. Longitudinal effects were analyzed using repeated measures analysis of variance. Results: The experimental group showed significant improvement in perceived knowledge, gatekeeper efficacy, perceived preparedness, and some aspects of attitude towards suicide compared to the control group, with effects declining over time but remaining statistically significant at the 3-month follow-up test. Conclusion This study is the first to evaluate the longitudinal effectiveness of Suicide CARE in a community population. Strategic integration of evidence-based gatekeeper training programs like Suicide CARE can contribute to community suicide prevention initiatives.